Marc Frahm
Stock Analyst at TD Cowen
(0.10)
# 4,141
Out of 4,820 analysts
16
Total ratings
15.38%
Success rate
-33.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Marc Frahm
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
SANA Sana Biotechnology | Upgrades: Buy | n/a | $1.76 | - | 2 | Jan 8, 2025 | |
TBPH Theravance Biopharma | Maintains: Hold | $10 → $9 | $9.74 | -7.60% | 3 | Aug 6, 2024 | |
INCY Incyte | Maintains: Buy | $88 → $80 | $59.53 | +34.39% | 3 | May 1, 2024 | |
CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $7.75 | - | 1 | Jun 15, 2023 | |
XLO Xilio Therapeutics | Initiates: Outperform | n/a | $0.77 | - | 1 | Nov 16, 2021 | |
NUVL Nuvalent | Initiates: Outperform | n/a | $75.20 | - | 1 | Aug 23, 2021 | |
ELEV Elevation Oncology | Initiates: Outperform | n/a | $0.36 | - | 1 | Jul 20, 2021 | |
JANX Janux Therapeutics | Initiates: Outperform | n/a | $32.26 | - | 1 | Jul 6, 2021 | |
DAWN Day One Biopharmaceuticals | Initiates: Outperform | n/a | $7.75 | - | 1 | Jun 21, 2021 | |
INZY Inozyme Pharma | Initiates: Outperform | n/a | $0.96 | - | 1 | Aug 18, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.60 | - | 1 | Feb 24, 2020 |
Sana Biotechnology
Jan 8, 2025
Upgrades: Buy
Price Target: n/a
Current: $1.76
Upside: -
Theravance Biopharma
Aug 6, 2024
Maintains: Hold
Price Target: $10 → $9
Current: $9.74
Upside: -7.60%
Incyte
May 1, 2024
Maintains: Buy
Price Target: $88 → $80
Current: $59.53
Upside: +34.39%
Cullinan Therapeutics
Jun 15, 2023
Initiates: Outperform
Price Target: n/a
Current: $7.75
Upside: -
Xilio Therapeutics
Nov 16, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.77
Upside: -
Nuvalent
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $75.20
Upside: -
Elevation Oncology
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.36
Upside: -
Janux Therapeutics
Jul 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $32.26
Upside: -
Day One Biopharmaceuticals
Jun 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.75
Upside: -
Inozyme Pharma
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $0.96
Upside: -
Feb 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.60
Upside: -